Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.

Kathleen M MooreHossein BorghaeiDavid M O'MalleyWoondong JeongShelly M SewardTodd M BauerRaymond P PerezUrsula A MatulonisKelli L RunningXiaoyan ZhangJose F PonteRodrigo Ruiz-SotoMichael J Birrer

Published in: Cancer (2017)

IMGN853 demonstrated a manageable safety profile and encouraging preliminary clinical activity, particularly in patients with ovarian cancer. The results establish a recommended phase 2 dosing of 6.0 mg/kg (based on adjusted ideal body weight) once every 3 weeks. Cancer 2017. © 2017 American Cancer Society. Cancer 2017;123:3080-7. © 2017 American Cancer Society.

Keyphrases

papillary thyroid
squamous cell
lymph node metastasis
cancer therapy
childhood cancer
drug delivery
open label
binding protein